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Transplantation Data
Treatment Group CB dose (x 10*6) T-cell dose (x 10*6) GVHD (score 1-10) Engraftment Survival
1 (CB alone) 0.5 - 10 - 1/37 (3) 1/37 (2.7%) 36/37 (97%)
2 (CB1 T) 1.0 – 3.0 3.0 3/8 (6) 3/8 (38%) 4/8 (50%)
3a (CB1 S59 T) 0.5 – 3.0 1.0 – 3.0 0/16 1/16 (6.3%) 16/16 (100%)
3b (CB1 S59 T) 3.0 9.0 1/8 (3) 6/8 (75%) 8/8 (100%)
3c (CB1 S59 T) 6.0 3.0 0/6 3/6 (50%) 6/6 (100%)
T- T lymphocyte, CB- Cord blood
Oral Presentations S161GVHD were minimal. Donor MHC high/c-kit+/lineage-/CD34-
stem cells were noted in the recipient bone marrow compartment
(Group3b). Although lineage specific markers for lymphoid,
myeloid and erythroid series were expressed in the host bone mar-
row and spleen mice by day 30, full hematological recovery was
delayed until 50-60 days after CBT. In-vitro mixed lymphocyte re-
action with S-59 treated T cells demonstrated a 6 fold increase in
Foxp3 + CD4 +CD25+ regulatory T cells after 72 hours of co-cul-
ture compared to control (p5 0.0002).
Conclusions: These results show improved cord blood engr-
aftment kinetics across a disparate H2 haplotype by adding pso-
ralen-treated donor T lymphocytes. Co-transplantation of
psoralen treated lymphocytes with CB cells facilitated durable en-
graftment of donor MHC high/c-kit+ cells in the marrow and
splenic compartments with complete but delayed hematopoietic
recovery. The low GVHD risk and excellent long-term survival
observed in this murine model suggests the potential for clinical
application.18
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Background: Various prospective trials which employed genetic al-
location of post-remission treatment have been performed to assess
the role of allogeneic hematopoietic cell transplantation (allo-HCT)
in the treatment of AML in CR1. However, it has been difficult to
clearly demonstrate the clinical benefit of allo-HCT in patients
with AML in CR1. A decision analysis with the Markov process is
a flexible and convenient analytical method that tracks the clinical
events that occur after a certain decision with different probabilities
over time. To address the role of allo-HCT for AML in CR1, we
performed a Markov decision analysis using newly collected clinical
data from 2029 patients.
Methods: Probabilities and other outcome data were derived from
a database of adult AML patients that was constructed from case re-
port files collected for this study.We included patients who were di-
agnosed with AML other than M3 between 1999 and 2006, aged 16
to 70 years, and who had achieved CR1 after 1 or 2 courses of induc-
tion chemotherapy. Using the software package TreeAge Pro, we
constructed a Markov decision model that compared 2 strategies:
allo-HCT in CR1 (HCT group) and no allo-HCT in CR1 (CTx
group). Quality-of-life (QOL) adjustments were made by incorpo-
rating time trade-off utilities that were derived from a questionnaire
to 13 physicians. The cycle length between state transitions was set at
3 months.
Results: A total of 2029 patients were eligible for this analysis. The
median age was 50 years, and the median follow-up of the surviving
patients was 4.1 years. The proportions of patients with favorable,
intermediate, unfavorable and unknown cytogenetic risk by
SWOG criteria were 20%, 54%, 17% and 9%, respectively. Thera-pies performed at CR1 were allo-HCT in 494 patients (24%) and
chemotherapy in 1535 patients (76%). Life expectancy of the
HCT group was longer than that of the CTx group (4.96 vs. 4.44
years, Table1). However, quality-adjusted life expectancy of the
HCT group was comparable to that of the CTx group (4.06 vs.
3.98 years). In patients with intermediate-risk or unfavorable-risk
AML, allo-HCT in CR1 was associated with a longer life expectancy
compared to the CTx group, and adjustment for QOL did not
change the preferred decision.
Conclusion: The results indicated that patients with intermediate-
or unfavorable-risk AML have a longer life expectancy and quality-
adjusted life expectancy with a decision of allo-HCT in CR1.
Life Expectancy and QOL-Adjusted Life Expectancy (years)
Allo-HCT in CR1 No Allo-HCT in CR1Life
Expectancy QOL-AdjustedLife
Expectancy QOL-AdjustedTotal 5.09 4.18 4.44 3.97
SWOG
Favorable 5.00 4.13 5.41 4.86
Intermediate 5.38 4.43 4.46 4.01
Unfavorable 4.66 3.74 3.27 2.9119
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The optimal approach for GVHD prophylaxis remains uncertain
and novel strategies are needed. It has been argued that, due to sub-
jectivity in scoring clinical signs of GVHD, additional, more objec-
tive endpoints should be used. One ofmore persuasive ones is the use
of SSI beyond the originally planned prophylaxis.We retrospectively
compared the incidence of GVHD and the use of SSI in 139 consec-
utive patients with advanced hematologic malignancies treated on
a phase II trial using HiCy as a single agent prophylaxis of GVHD
following HLA-matched related and unrelated BMT. We hypothe-
sized that use of this prophylactic strategy will promote tolerance
induction, improve the control of GVHD, and thereby decrease
the overall use of SSI. Patients, median age 49 (21-66), of whom
53% were not in remission at the time of transplant, received
HLA-matched related (n5 79) or unrelated (n5 60) BM after mye-
loablative BuCy conditioning. HiCy (50 mg/kg/day) was given on
days +3, and +4 as only planned GVHD prophylaxis. Patients with
acute grade II-IV GVHD were treated with methylprednisolone
1-2.5 mg/kg/day IV as a first line therapy, and those with visceral
GVHD also received calcineurin inhibitors (CNI) or other non-
CNI immunosuppressants. In the competing risk model (death and
graft failure as competing risks), the incidence of acute grade II-IV
and III-IVGVHDby day 200 was 50% and 16%, respectively. Thir-
teen percent of patients who developed acute grade II-IV GVHD
were not treated 15%were treated with steroids alone, 63%with ste-
roids plus a CNI and 9% with steroids plus non CNI-based agents.
Overall cumulative incidence of SSI use was 45%. Median time to
initiation of SSI was 42 (19-142) days and the median duration of
